W1163 Value of the Neutrophil to Lymphocyte Ratio (NLR) As a Predictive Tool of Disease Severity and Length of Hospitalizations in Ulcerative Colitis

Abotaga, Sherif Andrawes; Oliner, Charles; Goodman, Adam; Azab, Basem; Weiserbs, Kera F.; Agarwal, Manuj; Koczka, Charles; Purow, Elias; Gress, Frank G.

doi:10.1016/s0016-5085(09)63076-6

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eleven studies employed NLR as a potential tool to predict post-surgical hospital stay or development of various complications in CD [ 84 , 98 , 99 , 100 , 101 ], UC [ 93 , 102 , 103 , 104 , 105 ], or IBD [ 106 , 107 ].…”

Section: Resultsmentioning

confidence: 99%

“…UC: Abotaga et al [ 102 ] reported that higher NLR values were correlated with length of hospital stay (r 2 = 0.1703, p < 0.001) with a stronger correlation in white (r 2 = 0.2991, p = 0.003) compared to black patients (r 2 = 0.1112, p = 0.502); a near-significant relationship between NLR and an increased number of UC flares was also reported ( p = 0.07). Nishida et al (2020) [ 104 ] reported that in patients who underwent ileal pouch-anal anastomosis (IPAA), both a continuous NLR value ( p = 0.03) and a cutpoint of 2.15 (72.2% sensitivity, 67.7% specificity) were associated with the development of pouchitis.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Inflammatory Bowel Disease and Neutrophil–Lymphocyte Ratio: A Systematic Scoping Review

Langley

Guedry

Goldenberg

et al. 2021

JCM

View full text Add to dashboard Cite

Neutrophil–lymphocyte ratio (NLR) is a biomarker of the systemic inflammatory response. The objective of this systematic scoping review was to examine the literature on NLR and inflammatory bowel disease (IBD). PubMed, Embase, Cochrane CENTRAL, CINAHL, ClinicalTrials.gov, Cochrane Specialized Register, DOAJ, PDQT, Biosis Citation Index, Scopus, and Web of Science were systematically searched. A total of 2621 citations yielding 62 primary studies were synthesized under four categories: distinguishing patients with IBD from controls, disease activity differentiation, clinical outcome prediction, and association of NLR with other IBD biomarkers. Thirty-eight studies employed receiver operating characteristic (ROC) curve analysis to generate optimal NLR cutpoints for applications including disease activity differentiation and prediction of response to treatment. Among the most promising findings, NLR may have utility for clinical and endoscopic disease activity differentiation and prediction of loss of response to infliximab (IFX). Overall findings suggest NLR may be a promising IBD biomarker. Assessment of NLR is non-invasive, low cost, and widely accessible given NLR is easily calculated from blood count data routinely and serially monitored in patients with IBD. Further research is justified to elucidate how evaluation of NLR in research and clinical practice would directly impact the quality and cost of care for patients living with IBD.

show abstract